Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria

Basetty, V; Deruiter, J; Pathak, S; Dua, K; Dhanasekaran, M

Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria

Basetty, V Deruiter, J Pathak, S Dua, K

Dhanasekaran, M

Permalink

Publisher:: Elsevier
Publication Type:: Chapter
Citation:: Drug Delivery Systems for Metabolic Disorders, 2022, pp. 65-76
Issue Date:: 2022-01-01

Closed Access

	Filename	Description	Size
	3-s2.0-B9780323996167000244-main (1).pdf	Published version	482.27 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Basetty, V
dc.contributor.author	Deruiter, J
dc.contributor.author	Pathak, S
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Dhanasekaran, M
dc.date.accessioned	2023-02-15T21:02:23Z
dc.date.available	2023-02-15T21:02:23Z
dc.date.issued	2022-01-01
dc.identifier.citation	Drug Delivery Systems for Metabolic Disorders, 2022, pp. 65-76
dc.identifier.isbn	9780323996334
dc.identifier.uri	http://hdl.handle.net/10453/166169
dc.description.abstract	Porphyrias are known as disorders of the heme biosynthesis pathway. There are about eight metabolic disorders that make up the porphyrias. These eight metabolic disorders are porphyria cutanea tarda, acute intermittent porphyria, ALA-dehydratase deficiency porphyria, hepatoerythropoietic porphyria, variegate porphyria, hereditary coproporphyria, congenital erythropoietic porphyria, erythropoietic protoporphyria, and X-linked protoporphyria. These metabolic disorders can be classified as either erythropoietic or hepatic porphyria. Additionally, these metabolic disorders can be classified as either cutaneous or acute based on the signs and symptoms. This article looks at the pathophysiology, clinical manifestations, diagnosis, treatments, and novel drug therapy options of porphyrias in hopes of increasing awareness of these diseases and dosage forms among healthcare professionals.
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Drug Delivery Systems for Metabolic Disorders
dc.relation.isbasedon	10.1016/B978-0-323-99616-7.00022-0
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-15T21:02:22Z
pubs.publication-status	Published

Abstract:

Porphyrias are known as disorders of the heme biosynthesis pathway. There are about eight metabolic disorders that make up the porphyrias. These eight metabolic disorders are porphyria cutanea tarda, acute intermittent porphyria, ALA-dehydratase deficiency porphyria, hepatoerythropoietic porphyria, variegate porphyria, hereditary coproporphyria, congenital erythropoietic porphyria, erythropoietic protoporphyria, and X-linked protoporphyria. These metabolic disorders can be classified as either erythropoietic or hepatic porphyria. Additionally, these metabolic disorders can be classified as either cutaneous or acute based on the signs and symptoms. This article looks at the pathophysiology, clinical manifestations, diagnosis, treatments, and novel drug therapy options of porphyrias in hopes of increasing awareness of these diseases and dosage forms among healthcare professionals.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166169